Oncology Resource Center
Click on the subcategory below to find drug monographs for that particular area.
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi's sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
Elevated levels of three proteins detected in urine of early-stage pancreatic cancer patients
For patients with metastatic melanoma treated with mitogen-activated protein kinase (MAPK) inhibitors, gender, serum lactate dehydrogenase (LDH), BRAF genotype, and primary melanoma ulceration status are independent factors associated with treatment outcomes.
Lexicon announced top-line results from the Phase 3 study, TELESTAR, which evaluated oral telotristat etiprate in cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care.
Some performance indicators for mammography test sets are associated with aspects of clinical audit parameters.
Tyrosine kinase inhibitors (TKIs) appear to be safe in patients with chronic-phase (CP) chronic myeloid leukemia (CML) and chronic kidney disease (CKD).
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Featured courses from myCME
Radiation oncologists and residents will appreciate the experience of the renowned faculty of the Comprehensive ...
This activity is designed to change health provider attitudes on chronic pain and willingness to ...
Among the many issues clinicians face today, staying current with advances in medicine is becoming ...